Literature DB >> 3288952

Esophageal motor abnormalities in children and adolescents with scleroderma and mixed connective tissue disease.

J A Flick1, J T Boyle, D N Tuchman, B H Athreya, R A Doughty.   

Abstract

To determine the frequency and nature of esophageal motor abnormalities in children and adolescents with scleroderma syndromes and mixed connective tissue disease, esophageal manometry was performed on seven patients with progressive systemic sclerosis, four patients with mixed connective tissue disease, and two patients with linear scleroderma. A total of 73% of patients with progressive systemic sclerosis and mixed connective tissue disease had symptoms of esophageal dysfunction. A significant association between the presence of Raynaud phenomenon and esophageal symptoms was noted. Esophageal motor abnormalities were detected in 73% of patients with progressive systemic sclerosis and mixed connective tissue disease; these abnormalities were characterized by decreased lower esophageal sphincter pressure and abnormal peristalsis in the distal two thirds of the esophageal body. They resemble those described among adults with progressive systemic sclerosis and mixed connective tissue disease but were not related to disease duration or to the presence of Raynaud phenomenon. Patients with linear scleroderma did not have esophageal symptoms and demonstrated only nonspecific motor abnormalities that did not worsen during several years of follow-up.

Entities:  

Mesh:

Year:  1988        PMID: 3288952

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  2 in total

Review 1.  Clinical applications of gastrointestinal manometry in children.

Authors:  Jeana Hong
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2014-03-31

2.  Clinical characteristics of children with Juvenile Systemic Sclerosis: follow-up of 23 patients in a single tertiary center.

Authors:  Ricardo A G Russo; María M Katsicas
Journal:  Pediatr Rheumatol Online J       Date:  2007-05-01       Impact factor: 3.054

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.